Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

Inclusion CriteriaAdults with a confirmed diagnosis of unresectable, locally advanced and/or metastatic Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)Documented progression and measurable disease after ≥ 1 prior line of systemic therapy (≥ 2 and≤ 4 prior lines for NSCLC) with adequate washout period and resolution of treatment-related toxicities to ≤ Grade 2ECOG PS of 0-2 (0-1 for PDAC) and a life expectancy > 3 months in the opinion of the InvestigatorAdequate hematological, liver, and renal functionMen and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatmentExclusion CriteriaSymptomatic and/or untreated CNS or brain metastasis, pre-existing ILD or pericardial/pleural effusion of ≥ grade 2 or requiring chronic oxygen therapy for COPD or pleural effusionsSerious concomitant disorder including infectionKnown positive test for HIV, HCV, HBV surface antigenConcurrent malignancy in the previous 2 yearsPrior menin therapyRequiring treatment with a strong or moderate CYP3A inhibitor/inducerSignificant cardiovascular disease or QTcF or QTcB prolongation.Major surgery within 4 weeks prior to first doseWomen who are pregnant or lactating.